Transferrin Receptor Activity as a Marker in Transitional Cell Carcinoma of the Bladder

Başar, I.; Ayhan, Ayşe; Bircan, K.; Ergen, Ali; TAşAR,

doi:10.1111/j.1464-410x.1991.tb15101.x

Cited by 23 publications

(8 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Expression of TfR on the cell surface is upregulated in several cancers, including breast cancer [36], bladder cancer [37], prostate cancer [38], leukemia and lymphoma [39]. Likely, this is the result of the increased requirement for iron of rapidly growing cells, since other proliferating cells also have high surface expression of TfR in comparison to their quiescent or slower-growing counterparts [39,40].…”

Section: Iron and Cancermentioning

confidence: 99%

The Role of Iron Chelation in Cancer Therapy

Buss¹,

Torti²,

Torti³

2003

CMC

215

216

View full text Add to dashboard Cite

This review focuses on advances and strategies in the use of iron chelators as anti-tumor therapies. Although the development of iron chelators for human disease has focused primarily on their use in the treatment of secondary iron overload, chelators may also be useful anti-tumor agents. They can deplete iron or cause oxidative stress in the tumor due to redox perturbations in its environment. Iron chelators have been tested for their anti-tumor activity in cell culture experiments, animal models and human clinical trials. Largely for pragmatic reasons, clinical studies of the anti-tumor activity of iron chelators have generally focused on desferrioxamine (DFO), a drug approved for the treatment of iron overload. These studies have shown that DFO can retard tumor growth in many different experimental contexts. However, the activity of DFO is modest, and advances in the use of chelators as anti-cancer agents will require the development of new chelators based on new paradigms. Examples of iron chelators that have shown promising anti-tumor activity (in various stages of development) include heterocyclic carboxaldehyde thiosemicarbazones, analogs of pyridoxal isonicotinoyl hydrazone, tachpyridine, O-trensox, desferrithiocin, and other natural and synthetic chelators. Apart from their use as single agents, chelators may also synergize with other anti-cancer therapies. The development of chelators as anticancer agents is largely an unexplored field, but one with extraordinary potential to impact human cancer.

show abstract

Section: Iron and Cancermentioning

confidence: 99%

The Role of Iron Chelation in Cancer Therapy

Buss¹,

Torti²,

Torti³

2003

CMC

215

216

View full text Add to dashboard Cite

show abstract

“…Immunohistological staining of ABO isoantigen [8], T-antigen [8], Tn-antigen [11], TFR [2,12], or other growth factor receptors [5] may be useful. However, histological grading alone does not always correlate with the clinical course of the patients.…”

Section: Discussionmentioning

confidence: 99%

“…However, histological grading alone does not always correlate with the clinical course of the patients. Some investigators reported that TFR expression correlates well with histological grades using immunohistochemistry [2,12]. Because this method is a qualitative analysis, the results depend largely on examiners.…”

Section: Discussionmentioning

confidence: 99%

Flow cytometric evaluation of transferrin receptor in transitional cell carcinoma

et al. 1997

View full text Add to dashboard Cite

We evaluated flow cytometric (FCM) analysis of transferrin receptor (TFR) expression as a marker for the malignant potential in transitional cell carcinoma (TCC). TCCs from 55 patients were analyzed by FCM using an anti-TFR monoclonal antibody (CD71) and a TCC-specific monoclonal antibody (EH14), which recognizes most TCC cells irrespective of the grade. The cells were divided into subpopulations according to DNA ploidy determined simultaneously. TFR expression correlated well with the grade and the stage of the tumors. TFR expression of the aneuploid tumors was significantly higher than that of the euploid tumors in all subpopulations. EH14 expression did not correlate with the grade or the stage of the tumors. EH14 expression of the aneuploid tumors was significantly higher than that of the euploid tumors in the whole cell population but not in the subpopulations. In moderately differentiated tumors or in T1 tumors, TFR expression was higher in multiple or recurrent tumors than in simple tumors. The cell size or shape were not the primary reasons for the enhanced expression of TFR in the high-grade or the high-stage tumors; instead, overproduction of TFR may take place in these tumors. Clinically, many of the TCC tumors are grouped into G2 or T1 tumors, some of which will be invasive cancers. Quantitative analysis of TFR expression using FCM may be useful to predict the prognosis of these tumors.

show abstract

“…there are numerous examples of nuclear molecular imaging applications for the assessment of hormone and cell-surface receptor status (10,22,35,58). In the field of MRI, there have been attempts to monitor the expression levels of the transferrin receptor (tfR), which is linked to tumor grade and metastatic potential (9,32,67). the transferrin receptor is a cell-surface internalizing receptor responsible for almost all iron sequestration in mammalian cells.…”

Section: Molecularmentioning

confidence: 99%

Noninvasive Imaging of Breast Cancer

Medarova

2009

Biotechnology & Biotechnological Equipment

View full text Add to dashboard Cite

Transferrin Receptor Activity as a Marker in Transitional Cell Carcinoma of the Bladder

Cited by 23 publications

References 12 publications

The Role of Iron Chelation in Cancer Therapy

The Role of Iron Chelation in Cancer Therapy

Flow cytometric evaluation of transferrin receptor in transitional cell carcinoma

Noninvasive Imaging of Breast Cancer

Contact Info

Product

Resources

About